Stoke Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing groundbreaking antisense oligonucleotide (ASO) therapies aimed at addressing the root causes of severe genetic disorders. Based in Bedford, Massachusetts, the company leverages its proprietary technology platform to design and optimize ASOs, with a commitment to transforming the lives of patients afflicted by genetic diseases. Stoke's pioneering research and development efforts position it at the forefront of genetic medicine, making it a compelling prospect for institutional investors seeking exposure to the biopharmaceutical sector.